Loading...
XNAS
HBIO
Market cap33mUSD
Dec 05, Last price  
0.76USD
1D
4.81%
1Q
58.45%
Jan 2017
-75.16%
IPO
-82.62%
Name

Harvard Bioscience Inc

Chart & Performance

D1W1MN
XNAS:HBIO chart
P/E
P/S
0.36
EPS
Div Yield, %
Shrs. gr., 5y
2.86%
Rev. gr., 5y
-4.12%
Revenues
94m
-16.14%
67,431,00076,181,00083,407,00088,049,00085,772,000108,179,000108,864,000111,171,000105,171,000108,663,000108,664,000104,521,000101,882,000120,774,000116,176,000102,100,000118,904,000113,335,000112,250,00094,135,000
Net income
-12m
L+263.25%
-31,877,000-2,341,000-1,354,0001,673,0007,233,00019,015,0003,812,0002,370,000-1,830,0002,355,000-19,039,000-4,307,000-865,000-3,462,000-4,687,000-7,810,000-288,000-9,516,000-3,415,000-12,405,000
CFO
1m
-89.73%
5,195,0008,356,00012,055,0009,202,00016,509,00012,293,0006,348,0008,062,0004,060,0004,351,000705,0005,383,0001,057,0002,344,0008,047,0009,331,0001,262,0001,152,00014,028,0001,440,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
IPO date
Oct 21, 2013
Employees
436
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT